Overview of the Partnership
Wuhan Wansheng Biotechnology Co., Ltd. is GL Biochem's single most important manufacturing partner — a relationship that has defined the contours of our research peptide business since 2013 and continues to grow deeper with every passing year. Based in Wuhan's Optics Valley (光谷) — China's most concentrated hub of biotech and pharmaceutical R&D — Wansheng brings a rare combination of synthesis expertise, analytical rigour, and production scale that perfectly complements GL Biochem's own capabilities in Shanghai's Zhangjiang Hi-Tech Park.
The partnership began modestly: GL Biochem was seeking a secondary synthesis site capable of absorbing overflow demand during peak catalogue periods, and Wansheng — then a seven-year-old company with strong academic roots in Wuhan University's pharmacology departments — was looking for a blue-chip manufacturing client to anchor its expansion. The fit was immediately apparent. Both companies shared the same commitment to pharmacopoeial testing standards (USP, EP, ChP), both had invested heavily in automated SPPS equipment, and both had leadership teams with deep academic backgrounds in peptide chemistry.
What began as a simple contract manufacturing arrangement has evolved into a fully integrated strategic partnership. Today, GL Biochem and Wansheng operate what is effectively a dual-site, single-quality-system manufacturing network — each facility maintaining its own QC laboratory and batch release processes, but following harmonised SOPs, shared method libraries, and a joint analytical database that enables seamless product transfers between sites.
The breadth of the collaboration is difficult to overstate. Wansheng manufactures finished lyophilised peptide vials under the GL Biochem specification for over 500 catalogue SKUs. GL Biochem supplies Wansheng with Fmoc and Boc protected amino acid building blocks from our Shanghai production lines. Joint R&D teams work on novel peptide candidates. And both companies co-fund a shared analytical reference library of over 1,200 certified peptide standards — a resource that underpins the credibility of COA data across both businesses.
Manufacturing Capabilities & Shared Infrastructure
Wuhan Wansheng's primary manufacturing facility spans approximately 18,000 m² across three interconnected buildings on the outskirts of Wuhan's East Lake High-Tech Development Zone. The facility was purpose-built for pharmaceutical-grade peptide synthesis and has undergone three major expansion phases since its opening in 2012, with the most recent phase — completed in Q3 2024 — adding a fully enclosed ISO Class 7 cleanroom synthesis suite specifically designed for GLP-1 analogue production.
The synthesis floor houses more than 40 automated SPPS synthesisers of varying scales, from 50 mmol benchtop units used for R&D and feasibility studies through to 2,000 mmol (2 mol) production-scale reactors capable of generating multi-kilogram crude peptide batches in a single synthesis cycle. Equipment includes:
- CEM Liberty Blue microwave-assisted peptide synthesisers (×8, 0.05–5 mmol scale)
- Gyros Protein Technologies Tribute and Symphony synthesisers (×12, 0.1–25 mmol scale)
- Custom-built large-scale SPPS reactors (×6, 100–2,000 mmol scale) — designed in-house with GL Biochem's engineering team
- ABI/Applied Biosystems 430A legacy synthesisers retained for select difficult sequences (×4)
- Automated resin handling and cleavage systems integrated with the SPPS line
Downstream processing at the Wuhan facility is equally impressive. Six large-scale preparative HPLC systems — including two Shimadzu LC-20 preparative systems with 250 mm × 500 mm C18 columns and two Waters PREP 150 LC systems — handle purification of crude peptide material to ≥95%, ≥98%, and ≥99% purity grades depending on customer specification. A dedicated reverse-phase ion-pairing HPLC line handles hydrophobic sequences that would otherwise require speciality mobile phase conditions.
Lyophilisation capacity at the Wuhan facility consists of six validated freeze-dryers: two Virtis Genesis 25 EL units, two Christ EPSILON 2-40D systems, and two custom-built large-capacity lyophilisers rated for 400 L chamber volume each. These units handle the majority of GL Biochem's vial-format output destined for research markets. Every lyophilisation cycle is logged against a validated protocol with full temperature-mapping data and is subject to final QC release (HPLC purity, appearance, reconstitution test, residual moisture) before despatch.
Product Scope & What We Co-Manufacture
The range of products manufactured at Wuhan Wansheng on behalf of GL Biochem — or supplied by GL Biochem to Wansheng as building blocks — is extensive and spans virtually every category in our catalogue. Key product areas include:
- Pharmaceutical peptide APIs: GLP-1 receptor agonists (semaglutide analogues, liraglutide, tirzepatide fragments), growth hormone secretagogues (ipamorelin, GHRP-2, GHRP-6, CJC-1295 series), melanocortin peptides (melanotan-II, PT-141), thymic peptides (thymosin α1, thymosin β4 fragments, thymopentin), and immunomodulatory peptides (BPC-157, TB-500 series)
- Cosmetic peptides: Palmitoyl pentapeptide-4 (Matrixyl), acetyl hexapeptide-3 (Argireline), copper peptide GHK-Cu, leuphasyl, syn-ake (dipeptide diaminobutyroyl benzylamide diacetate), and over 80 additional cosmetic actives manufactured under ISO 22716 cosmetic GMP conditions
- Research peptides (lyophilised vials): The full GL Biochem research peptide catalogue — covering over 400 vial-format catalogue items — is lyophilised and vial-filled at the Wuhan facility, then released by our joint QC team and shipped to customers worldwide under the GL Biochem brand
- Custom peptide synthesis: Wansheng handles a significant volume of GL Biochem's custom synthesis orders requiring scale >5 grams — particularly those involving difficult sequences, stapled peptides, or PEGylated constructs where speciality equipment is required
In the reverse direction, GL Biochem's Shanghai facility supplies Wuhan Wansheng with Fmoc and Boc protected amino acid building blocks that Wansheng incorporates into its own synthesis workflows. GL Biochem produces these building blocks at significantly lower cost than Wansheng could source them from European or Japanese suppliers, and the two companies have a long-term supply agreement fixing prices and minimum delivery quantities on a rolling 12-month basis.
Joint R&D & Innovation
Beyond the commercial manufacturing relationship, GL Biochem and Wuhan Wansheng have established a formal Joint R&D Committee that meets quarterly — alternating between Shanghai and Wuhan — to review ongoing collaborative research projects and agree priorities for new joint initiatives. The committee is co-chaired by GL Biochem's Chief Science Officer and Wansheng's Head of Peptide Chemistry, and includes representatives from both companies' analytical, regulatory, and business development teams.
Current active joint R&D programmes include:
- Next-generation peptide stapling: Development of novel all-hydrocarbon and thioether-bridged stapled peptide methodologies for improved helical stability and cell penetration — targeting oncology and antiviral research markets
- Long-acting GLP-1 analogues: Optimisation of fatty acid conjugation chemistry for once-weekly and once-monthly dosing candidate peptides — leveraging Wansheng's large-scale coupling capabilities and GL Biochem's analytical expertise in fatty acid conjugate characterisation
- Phosphopeptide synthesis optimisation: Addressing yield and purity challenges associated with multi-phosphorylated sequences, with the goal of bringing phosphopeptide API synthesis in-house rather than outsourcing to specialist CROs
- Novel cosmetic peptide candidates: Three undisclosed cosmetic peptide candidates currently in in-vitro efficacy screening, co-developed with a European cosmetics formulation house
Several jointly developed synthesis protocols have been filed as joint IP with both the China National Intellectual Property Administration (CNIPA) and the European Patent Office (EPO). These patents cover novel methods for the solid-phase synthesis of difficult hydrophobic sequences and represent a meaningful competitive moat for both companies in the high-purity pharmaceutical peptide market.
Quality Systems & Regulatory Compliance
Quality is the foundation of the GL Biochem–Wuhan Wansheng partnership. Both facilities maintain independent ISO 9001:2015 certifications (Shanghai: SGS cert. GB24/0XXXXX; Wuhan: TÜV SÜD cert. MS-XX/XXXXX) and operate under harmonised cGMP manufacturing practices aligned with ICH Q7 (API Manufacturing) and ICH Q11 (Development and Manufacture of Drug Substances).
A formal Quality Agreement governs all aspects of the manufacturing relationship, including:
- Batch record format and content requirements
- In-process control (IPC) checkpoints and acceptance criteria
- Final release testing specifications (HPLC purity ≥98%, MS confirmation, AAA, moisture, endotoxin, sterility)
- Deviation and out-of-specification (OOS) investigation procedures
- Change control — any change to manufacturing method, equipment, or raw material source requires joint approval
- Mutual audit rights — both companies conduct annual GMP audits at each other's facilities
- Data integrity requirements per ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate)
Analytical testing for jointly manufactured products is distributed between the two QC laboratories based on equipment capability and workload. GL Biochem's Shanghai QC lab — housing three Agilent 1260/1290 HPLC systems, an Agilent 6545 QTOF mass spectrometer, an Agilent 7900 ICP-MS, and a Metrohm 899 Karl Fischer titrator — handles high-resolution mass spectrometry confirmation, elemental impurity analysis, and optical rotation measurements. Wansheng's QC lab performs routine HPLC purity analysis, amino acid analysis (Hitachi L-8900), and endotoxin testing (LAL kinetic turbidimetric) for the bulk of vial-format batch releases.
Market Reach & Shared Customers
The GL Biochem–Wuhan Wansheng partnership collectively serves customers in over 50 countries across six continents. While GL Biochem's international sales team handles direct customer relationships in North America, Europe, Australia, the Middle East, and Southeast Asia, Wansheng brings its own domestic Chinese customer base — including several large Tier-1 Chinese pharmaceutical companies sourcing peptide APIs for domestic and export-registered drug products — to the combined network.
This domestic–international complementarity means that the two companies rarely compete for the same customers, and instead reinforce each other's market positions. GL Biochem provides Wansheng with international credibility and access to regulatory documentation frameworks required by Western regulators (FDA, EMA, TGA). Wansheng provides GL Biochem with access to Chinese pharmaceutical procurement networks that would otherwise require years of relationship-building to penetrate independently.
Several GL Biochem's largest international accounts — including biotech companies in the United States and Germany procuring GLP-1 analogue material for Phase I/II clinical trials — receive product manufactured at the Wuhan facility under GL Biochem's quality umbrella, with GL Biochem's CoA, DMF documentation, and technical support. This arrangement has been pivotal in GL Biochem's ability to scale supply rapidly for fast-moving clinical programmes without capital expenditure at the Shanghai site.